Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Support Care Cancer. 2002 Mar;10(2):88-95. Epub 2001 Aug 23.

Delayed emesis: incidence, pattern, prognostic factors and optimal treatment.

Author information

  • 1Medical Oncology Division, Arcispedale S. Anna, Ferrara, Italy. roila.fausto@libero.it


Delayed emesis has been arbitrarily defined as vomiting and/or nausea beginning, or persisting for, more than 24 h after chemotherapy administration. Acute emesis is the most important prognostic factor for delayed emesis. Owing to the relatively high incidence and severity all patients treated with cisplatin > or = 50 mg/m(2) should receive antiemetic prophylaxis. In these patients a combination of dexamethasone plus metoclopramide or a 5-HT3 antagonist is the most efficacious regimen. All patients submitted to moderately emetogenic chemotherapy, such as cyclophosphamide, carboplatin, doxorubicin and epirubicin, should also receive antiemetic prophylaxis with oral dexamethasone to prevent delayed emesis.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk